As companies face growing pressure to disclose their environmental and social impacts, ESG reporting has become a core part of doing business. Standards bring consistency and credibility to these ...

GRI Bio (GRI) announced topline data from the Phase 2a GRI-0621-IPF-02 clinical trial evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis. The study met its primary endpoint and ...

GRI Bio (GRI) announced the presentation of preclinical data demonstrating its lead program GRI-0621 reduces important inflammatory and fibrotic drivers in Idiopathic Pulmonary Fibrosis. The data were ...

The European Financial Reporting Advisory Group (EFRAG) and the Global Reporting Initiative (GRI) released a joint statement announcing the interoperability of their respective reporting standards, ...

GRI Bio, Inc. (NASDAQ: GRI) on Wednesday shared topline data from the Phase 2a GRI-0621-IPF-02 trial evaluating GRI-0621 for idiopathic pulmonary fibrosis. IPF is a chronic, progressive lung disease ...

The International Financial Reporting Standards Foundation and the Global Reporting Initiative said Thursday they have reached a collaboration agreement to coordinate their standard-setting and work ...

Seth Engel, Olga Gidalevitz Ph.D. The Global Reporting Initiative (GRI) published two new topic standards—GRI 102: Climate Change (2025) and GRI 103: Energy (2025). These standards will replace GRI ...

Positive interim 2-week safety and biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”) Continued momentum with completed ...